Catherine Owen Adams’ appointment marks a significant step forward for Acadia Pharmaceuticals as it enters a critical phase of growth. Her impressive track record at Bristol Myers Squibb and Johnson & Johnson demonstrates her ability to lead large teams, manage expansive portfolios, and drive innovation across multiple therapeutic areas. Acadia is well-positioned to leverage her strategic vision to accelerate development in central nervous system disorders and rare diseases. With its current commercial successes and a promising pipeline, Adams’ leadership will likely bolster Acadia’s long-term impact on patient outcomes.